Previous 10 | Next 10 |
2020 looks to be an important year for Karyopharm Therapeutics (NASDAQ: KPTI) . First, Karyopharm expects to share the results from its ongoing phase 3 clinical trial. It also should receive feedback from European regulators on an earlier pivotal trial in multiple myeloma -- a type of cancer....
-- Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis® and Low Dose Dexamethasone Demonstrates 71% Overall Response Rate, Including a Complete Response Rate of 21%, in Patients with Heavily Pretreated, Kyprolis-Naïve Multiple Myeloma -- -- All Oral Regimen o...
-- All Oral Regimen of Once Weekly Selinexor in Combination with Daily Pomalyst ® and Low Dose Dexamethasone Demonstrates 56% Overall Response Rate in Pomalyst ® -Naïve and Revlimid ® -Relapsed or -Refractory Myeloma with Progression-Free Survival of 12.2 Months -- ...
The healthcare sector seems to be waking up over the past several weeks. Political uncertainty has been hurting healthcare stocks throughout the past year, but this uncertainty seems to be dissipating as the Presidential election approaches, which is being a major tailwind for the healthcare ...
ASLAN Pharmaceuticals (NASDAQ: ASLN ) +85% on positive ASLAN004 data. More news on: ASLAN Pharmaceuticals Limited, Akari Therapeutics, Plc, Evofem Biosciences, Inc., Stocks on the move, Read more ...
Can-Fite BioPharma (NYSEMKT: CANF ) +51% . after 9M results . More news on: Can-Fite BioPharma Ltd., ASLAN Pharmaceuticals Limited, SORL Auto Parts, Inc., Stocks on the move, Read more ...
Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...
Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...
-- Updated Results from the Pomalyst® and Kyprolis® Arms of the Phase 1b/2 STOMP Study Evaluating Selinexor in Combination with Other Approved Myeloma Therapies in Relapsed or Refractory Multiple Myeloma to be Highlighted -- -- Other Key Presentations Include New Data from t...
"Sloth makes all things difficult, but industry all easy; and he that riseth late must trot all day, and shall scarce overtake his business at night; while laziness travels so slowly, that poverty soon overtakes him .”― Benjamin Franklin Karyopharm Therapeutics ( KPTI ) re...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress PR Newswire – Achieves Second Quarter 2024 Total Revenue of $42.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.0 Million ; Positive Momentum e...
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...